Quoin Pharmaceuticals. Ltd Sponsored ADR QNRX 深 滬
已收盤 02-06 16:00:00 美东时间
7.14
-0.680
-8.70%
華盛通- 最 高8.005
- 今 開7.82
- 成交量 1.76万股
- 最 低 7.14
- 昨 收 7.82
- 總市值 3605.50万
- 52周最高 41.80
- 市盈率 靜 --
- 換手率 0.35%
- 52周最低 5.01
- 委 比 -32.89%
- 總股本 504.97万
- 歷史最高 1417500.00
- 量 比 0.48
- 振 幅 11.06%
- 歷史最低 5.824
- 每 手 1
- 風險率 3.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Quoin Pharmaceuticals Submits Orphan Drug Designation Application To Japan's MHLW For QRX003 To Treat Netherton Syndrome
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that following a successful meeting with
01-27 21:37
Quoin Pharmaceuticals Submits Application For Breakthrough Medicine Designation With Saudi Food And Drug Authority For QRX003 To Treat Netherton Syndrome
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has filed an application for
01-20 21:35
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Akanda (NASDAQ:AKAN) stock rose 28.9% to $1.22 during Friday's pre-mar...
2025-12-05 20:05
Quoin Pharmaceuticals Q3 EPS $(6.71) Misses $(6.50) Estimate
Quoin Pharmaceuticals (NASDAQ:QNRX) reported quarterly losses of $(6.71) per share which missed the analyst consensus estimate of $(6.50) by 3.15 percent. This is a 59.21 percent increase over losses of $(16.45) per
2025-11-06 21:34
Quoin Pharmaceuticals Announces Recruitment Of Three Additional Pediatric Patients For Its Investigator-Led Netherton Syndrome Study And Reports 9-month Results From The First Patient Treated With QRX003 Showing Completely Healed Skin After 9 Months Of 'Whole Body' Treatment
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical stage, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and
2025-10-28 20:34
Quoin Pharmaceuticals Announces Recruitment of Three Additional Patients in Investigator Pediatric Netherton Syndrome Study and Provides Positive 9 month ‘Whole Body’ Data Update from Ongoing Study
Quoin Pharmaceuticals Ltd. announces the recruitment of three additional pediatric patients in its Netherton Syndrome (NS) study and reports positive 9-month clinical data from the first pediatric patient. The patient experienced complete skin healing, with IGA improving from 4 (severe) to 0 (clear), and pruritus reduced from 5 to 0. No adverse events were reported after 9 months of QRX003 treatment. The patient no longer requires medications lik...
2025-10-28 12:30
Here’s Why Quoin Pharmaceuticals Stock (QNRX) Exploded Today
Quoin Pharmaceuticals ($QNRX) stock skyrocketed by about 157% on Friday after a...
2025-10-11 03:05
Quoin Pharmaceuticals (QNRX) Stock Is Skyrocketing Friday: What's Going On?
Quoin Pharmaceuticals shares are trading higher Friday morning after the company announced a private placement financing of up to $104.5 million.
2025-10-11 00:31
Quoin Pharmaceuticals shares are trading higher. The company announced a $104.5 million private placement.
Quoin Pharmaceuticals shares are trading higher. The company announced a $104.5...
2025-10-10 21:34
Quoin Pharma Announces $104.5M Private Placement, Including $16.5M Upfront and $88M In Warrant-Linked Upside Priced Above Prior Close
Quoin Pharmaceuticals Ltd. (NASDAQ:QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has entered into a securities
2025-10-10 21:27
